Jane C. Davies

1. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
   2021/03/18 by Edith T. Zemanick, Jennifer L. Taylor‐Cousar, Jane C. Davies +19 · 2 citations
   Health Professions · Medicine · #Adverse effect #Confidence interval #Cystic Fibrosis Research Advances #Cystic fibrosis #Cystic fibrosis transmembrane conductance regulator #Gastroenterology #Internal medicine #Ivacaftor #Medicine #Neonatal Respiratory Health Research #Pediatric health and respiratory diseases #Pediatrics #Tolerability
2. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
   2016/11/16 by Eric W.F.W. Alton, Eric W F W Alton, Jeffery M Beekman +59 · 1 citation
   Biochemistry, Genetics and Molecular Biology · Engineering · #Virus-based gene therapy research #RNA Interference and Gene Delivery #Energy Harvesting in Wireless Networks
3. Adverse reactions to trimethoprim/sulfamethoxazole for melioidosis eradication therapy: An evaluation of frequency and risk factors
   2024/11/08 by Genevieve E. Martin, Joshua Bramwell, Eden Gadil +5 · 1 voice · 1 citation
   Agricultural and Biological Sciences · Medicine · #Burkholderia infections and melioidosis #Moringa oleifera research and applications